- Home
- TLSA vs NAAS Comparison
TLSA vs NAAS Comparison
Compare TLSA & NAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLSA | NAAS |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United Kingdom | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.1M | 50.8M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TLSA | NAAS |
|---|---|---|
| Price | $0.58 | $1.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.98 | N/A |
| AVG Volume (30 Days) | ★ 491.6K | 21.7K |
| Earning Date | 05-01-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $1.40 |
| 52 Week High | $1.90 | $4.10 |
Technical Indicators
Market Signals| Indicator | TLSA | NAAS |
|---|---|---|
| Relative Strength Index (RSI) | 29.22 | 30.98 |
| Support Level | $0.57 | N/A |
| Resistance Level | $1.21 | $3.39 |
| Average True Range (ATR) | 0.08 | 0.33 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 4.32 | 11.02 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.